Angiotensin receptor blockers for the treatment of COVID-19 and its comorbidities
Sign Up to like & getrecommendations! Published in 2020 at "Pharmacological Research"
DOI: 10.1016/j.phrs.2020.104958
Abstract: My recent report (Saavedra, 2020a) warned about the danger of removing ARBs from patients suffering from COVID-19 comorbidities, calling for definitive data analysis to determine whether ARB administration benefited COVID-19 patients. Huang and colleagues disagreed… read more here.
Keywords: covid patients; receptor blockers; covid comorbidities; blockers treatment ... See more keywords
OLD AND NEW EQUATIONS FOR MAXIMAL HEART RATE PREDICTION IN PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION ON BETA-BLOCKERS TREATMENT. RESULTS FROM THE MECKI SCORE DATASET.
Sign Up to like & getrecommendations! Published in 2022 at "European journal of preventive cardiology"
DOI: 10.1093/eurjpc/zwac099
Abstract: BACKGROUND Predicting maximal heart rate (MHR) in heart failure and reduced ejection fraction (HFrEF) still remains a major concern. In such a context, the Keteyian equation is the only one derived in a HFrEF cohort… read more here.
Keywords: maximal heart; equation; blockers treatment; heart ... See more keywords
Interleukin-1 blockers for the treatment of recurrent pericarditis: pathophysiology, patient reported outcomes and perspectives.
Sign Up to like & getrecommendations! Published in 2023 at "Journal of cardiovascular pharmacology"
DOI: 10.1097/fjc.0000000000001435
Abstract: ABSTRACT Recurrent pericarditis (RP) is the most troublesome complication of acute pericarditis reflecting an unresolving inflammation of the pericardial sac around the heart and associated with significant morbidity. Recent studies have shown interleukin-1 (IL-1) signaling… read more here.
Keywords: pathophysiology; pericarditis; recurrent pericarditis; blockers treatment ... See more keywords